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NEUROSURGERY

The Hydrogel Endovascular Aneurysm Treatment
Trial (HEAT): A Randomized Controlled Trial of the
Second-Generation Hydrogel Coil
BACKGROUND: Aneurysm recurrence after coiling has been associated with aneurysm
growth, (re)hemorrhage, and a greater need for follow-up. The second-generation
HydroCoil Embolic System (HES; MicroVention, Inc) consists of a platinum core with
integrated hydrogel and was developed to reduce recurrence through enhancing packing
density and healing within the aneurysm.
OBJECTIVE: To compare recurrence between the second-generation HES and bare
platinum coil (BPC) in the new-generation Hydrogel Endovascular Aneurysm Treatment
Trial (HEAT).
METHODS: HEAT is a randomized, controlled trial that enrolled subjects with ruptured or
unruptured 3- to 14-mm intracranial aneurysms amenable to coiling. The primary endpoint
was aneurysm recurrence using the Raymond-Roy scale. Secondary endpoints included
minor and major recurrence, packing density, adverse events related to the procedure
and/or device, mortality, initial complete occlusion, aneurysm retreatment, hemorrhage
from target aneurysm during follow-up, aneurysm occlusion stability, and clinical outcome
at final follow-up.
RESULTS: A total of 600 patients were randomized (HES, n = 297 and BPC, n = 303),
including 28% with ruptured aneurysms. Recurrence occurred in 11 (4.4%) subjects in the
HES arm and 44 (15.4%) subjects in the BPC arm (P = .002). While the initial occlusion rate
was higher with BPC, the packing density and both major and minor recurrence rates were
in favor of HES. Secondary endpoints including adverse events, retreatment, hemorrhage,
mortality, and clinical outcome did not differ between arms.
CONCLUSION: Coiling of small-to-medium aneurysms with second-generation HES
resulted in less recurrence when compared to BPC, without increased harm. These data
further support the use of the second-generation HES for the embolization of intracranial
aneurysms.
KEY WORDS: Bare platinum coil, Coil embolization, Endovascular, HydroCoil Embolic System, Intracranial
aneurysm, Randomized controlled trial
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hile coil embolization of intracranial
aneurysms has emerged as an effective
minimally invasive treatment for select
intracranial aneurysms, concern has lingered regarding recurrence. Aneurysm recurrence ranges

from 15% to 33% at 18 mo and has been
hypothesized to be driven by unorganized and
unstable thrombus formation and absence of
neointima formation at the neck of coiled
aneurysms.1-4 Recurrence has been associated

ABBREVIATIONS: BPC, bare platinum coil; CI, confidence interval; FDA, Food and Drug Administration; HEAT,
Hydrogel Endovascular Aneurysm Treatment; HES, HydroCoil Embolic System; HPB, Health Protection Branch;
MRA, magnetic resonance angiogram; mRS, modified Rankin Scale; OR, odds ratio; RR, Raymond-Roy; SAE, serious
adverse event; SD, standard deviation
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with the need for greater imaging follow-up, additional procedures, and target aneurysm (re)hemorrhage, which potentially
increases morbidity and mortality.1,5 Newer coils, including
bioactive coils, have not succeeded in reducing recurrence.6-9
The HydroCoil Embolic System (HES) (MicroVention, Inc,
Aliso Viejo, California) is a recent advance in coil mechanics,
which includes platinum coils containing a hydrogel polymer
that, once in contact with blood, expands to fill the coil lumen.
A body of evidence has linked both lower packing density and
poor healing within the aneurysm to higher recurrence rates,
and hence the design of HES to improve both coil packing
density and healing within aneurysms and at the neck.10-12
Animal studies have shown that HES achieves thicker neointima
along the aneurysm wall and neck, higher endothelial deposition
in the neck, higher cellular response, and better aneurysm
occlusion than bare platinum coils (BPCs).13-15 Clinical trials on
the first-generation HES demonstrated a trend toward reduced
recurrence with HES; however, its widespread adoption was
impeded by challenging handling properties.3,16,17 A secondgeneration HES was developed to overcome the technical difficulties associated with first-generation HES. The new-generation
Hydrogel Endovascular Aneurysm Treatment Trial (HEAT) was
designed to investigate whether the second-generation HES
reduces recurrence without an increase in adverse outcomes after
coiling of ruptured and unruptured small-to-medium intracranial
aneurysms when compared with BPC.

States and Canada. The study protocol was approved by the institutional review boards at Northwestern University, the Mayo Clinic, and
all participating study sites.18 The study was funded by MicroVention,
Inc (Aliso Viejo, California) through a grant that was housed at Northwestern University and Mayo Clinic but was independently managed
by the senior author (B.R.B.) with his research team through Northwestern University and Mayo Clinic. The funder, MicroVention, Inc,
had no role in the design or operation of the trial. However, the
funder was informed about serious adverse events (SAEs) throughout
the duration of the trial. The principal investigator had no relationship
with MicroVention beyond the funding of the study. This study was
initially conceived as the principal investigator’s master’s thesis as part
of Northwestern University’s Masters of Clinical Investigation Program.
An independent imaging core lab (A.J.D. and J.A.S.) reviewed all
angiographic imaging. Clinical outcomes and events were independently monitored and then reviewed by a Data Safety Monitoring
Board. Clinical trial registration information for this study can be found
at https://clinicaltrials.gov/ct2/show/NCT01407952 with the unique
identifier “NCT01407952.”

Participants

METHODS

Subjects were eligible for enrollment if they were between 18 and 75 yr
of age with an untreated intracranial aneurysm (ruptured or unruptured)
between 3 and 14 mm in size, which was amenable to coil embolization.
Patients with ruptured aneurysms were eligible if their Hunt and Hess
grade was ≤3. Exclusion criteria included the presence of concurrent
intracranial pathologies or presence of serious comorbidities. Prior to
randomization, informed consent was obtained from patients or a legally
authorized representative following Good Clinical Practice guidelines. A
detailed listing of inclusion and exclusion criteria is provided in the study
protocol.18

Trial Design

Interventions

HEAT is an investigator-initiated, randomized, controlled trial that
aimed to compare second-generation HES to BPC in the treatment of
ruptured or unruptured, small-to-medium-sized aneurysms (3-14 mm).
A total of 600 subjects were enrolled at 46 study centers in the United

For subjects randomized to the BPC arm, any BPC approved by the
Food and Drug Administration (FDA) or the Health Protection Branch
of Health Canada (HPB) was allowed and treatment consisted exclusively of BPCs. For subjects randomized to the HES arm, at least 90%
(of the total implanted coil length) of any FDA or HPB approved secondgeneration HES was used; BPCs were allowed for up to 10% of the
total implanted coil length. The use of bioactive and other types of
coils was not permitted. Assist devices including balloons and stents were
permitted at the discretion of the performing physician. The use of flow
diverters, however, was not permitted.
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Outcomes
The primary endpoint of the HEAT trial was aneurysm recurrence
defined as any progression on the Raymond-Roy (RR) occlusion scale
(Figure 1) during final follow-up.19 The secondary endpoints of the
trial included initial packing density, initial rate of complete occlusion,
device- and/or procedure-related adverse events, mortality rate, clinical
outcome at the 18- to 24-mo follow-up assessed by the modified Rankin
Scale (mRS), retreatment rates, hemorrhage from the coiled aneurysms
at any time during follow-up, aneurysm occlusion stability (assessed by
any change in volumetric occlusion as evaluated by the Meyers scale
presented in Figure 2), minor recurrence, and major recurrence.20 Major
recurrence was defined as an increase in the RR scale from 1 to 3, 2 to
3, or a 3 with an increase in the Meyers scale. Minor recurrence was
defined as an increase in the RR scale from 1 to 2. Packing density

www.neurosurgery-online.com
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FIGURE 1. Raymond-Roy aneurysm occlusion classification scale.19 Complete aneurysm occlusion; residual aneurysm neck; residual aneurysm
dome.

FIGURE 2. Aneurysm occlusion grading system as reported by Meyers et al.20 Grade 0: complete and total aneurysm occlusion. Grade 1: ≥90% volumetric
aneurysm occlusion. Grade 2: 70% to 89% volumetric aneurysm occlusion. Grade 3: 50% to 69% volumetric aneurysm occlusion. Grade 4: 25% to 49%
volumetric aneurysm occlusion. Grade 5: volumetric aneurysm occlusion.

was estimated by dividing the estimated volume of the coils used by the
estimated volume of the aneurysm. The volume of the coils was determined by summing the volume of all coils used. The volume of each
coil was calculated by multiplying the square of the coil diameter as
found in coil brochures provided by the manufacturers by the length
used by π /4. The volume of the aneurysm was calculated assuming the
shape of an ellipsoid, and multiplying the height × length × width ×
π and dividing by 6, where the aneurysm measurements were observed
during an angiogram. Clinical outcome (mRS) was assessed at the 18- to
24-mo follow-up, with missing values imputed as the last observed value
carried forward or as 6 if the patient died. Lastly, adverse events, including
SAEs defined as life-threatening, disabling, resulting in prolonged hospitalization or death, and designated by treating physicians, were reported
in alignment with FDA and HPB regulations. All adverse events and
essential data points were adjudicated in alignment with FDA Risk-Based
Monitoring guidance.21 Adverse events were designated as unanticipated and related to device and/or procedure at the discretion of the
sites.

NEUROSURGERY

Timeline
Both subject randomization and endovascular intervention were
performed on the same day, which was considered day 0. Initial and
follow-up clinical assessments were performed at 1 d, 3- to 28-d, 3- to
12-mo, and 18- to 24-mo follow-up intervals. Imaging parameters,
angiography and/or magnetic resonance angiogram (MRA), were
evaluated at the 3- to 12-mo and 18- to 24-mo visits. Whenever both
MRA and catheter angiography were performed, the catheter angiographic evaluation was considered for outcome assessment. For ruptured
aneurysms, the National Institutes of Health Stroke Scale and Hunt and
Hess scale were recorded but not included in the trial analysis.

Sample Size
Sample size was determined based on the assumption that the use
of second-generation HES to embolize intracranial aneurysms could
achieve a 30% lower recurrence rate than with the use of BPC. Assuming
a BPC major recurrence rate of 33%—as published in the HELPS
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trial—a sample size of 600 patients provided the HEAT trial with 80%
power to detect an improvement in recanalization rates to 22.8% using
a chi-square test at a type I error rate of 5%.

Randomization and Blinding
After informed consent was signed, subjects were randomized in a 1:1
allocation to either the HES group or the BPC group using DATATRAK
(DATATRAK International, Inc, Mayfield Heights, Ohio), the study’s
Electronic Data Capture; randomization was stratified by participation
site. Patients were given a study identification number that was used for
clinical data extraction. Submitted imaging studies were evaluated by
the Imaging Core Lab, which was blinded to the type of the coil used
for treatment. Treating physician and subjects were not blinded to the
treatment coil.

Statistical Methods
The analysis for the primary outcome was based on the intent-to-treat
principle. For missing outcome data, multiple imputation methods were
used, creating 5 datasets. Results were combined over the imputation
analyses to present valid univariate inferences for treatment group.
Due to the nature of the data, secondary analyses of the primary
outcome and all secondary outcomes were based on a per-protocol
analysis. Baseline demographics are presented as counts and percentages
(categorical characteristics), or mean and standard deviation (SD) for age,
and aneurysm dimension. Logistic regression models were fit to estimate
odds ratios (OR) and 95% CI for recurrence. The secondary analysis was
per protocol, with a chi-square test to determine if the recurrence rates
differed by coil type, and a logistics regression model adjusted for rupture
status, initial RR scale, maximal aneurysm circumference, and neck
diameter. As a further sensitivity analysis, an intent-to-treat analysis was
conducted, assuming patients without imaging follow-up had aneurysm
recurrence. Secondary outcomes were analyzed with a chi-square test or
Fisher’s exact test when event rates were restrictive (minor or major recurrence, adverse events related to device or procedure, mortality, initial
occlusion, retreatment, and hemorrhage), Cochran-Armitage trend test
(number of adverse events related to device or procedure per person),
independent t-test (packing density), Wilcoxon rank-sum test (clinical
outcome), or generalized linear models with a logit link function to
examine occlusion stability over time. All analyses were performed using
SASv9.2 (Cary, North Carolina) and run at a 5% type I error rate.

RESULTS
Participant Flow and Recruitment
A total of 600 out of 3971 screened subjects were enrolled in
the HEAT study between May 2012 and January 2016 (Figure 3).
After patient randomization, 297 were assigned to the HES arm
and 303 were assigned to the BPC arm. Information pertaining
to the primary outcome was available from 251 (84.5%) subjects
in the HES arm (222 from 18- to 24-mo imaging, 29 from 3to 12-mo imaging) and 266 (87.8%) from the BPC arm (231
from 18- to 24-mo imaging, 35 from 3- to 12-mo imaging).
In the HES arm, 17 patients were lost to follow-up, 7 patients
expired, 7 subjects voluntarily withdrew from the study, and 17
subjects were not eligible for primary endpoint analysis for other
reasons. In the BPC arm, 17 patients were lost to follow-up, 9
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patients expired, 11 subjects voluntarily withdrew, and 10 subjects
were not eligible for primary endpoint analysis for other reasons
(Table, Supplemental Digital Content 1). Of note, some of
the patients who exited the study were still eligible for primary
endpoint analysis, as they had 3- to 12-mo imaging studies.
Baseline Characteristics
Patient demographic and clinical characteristics were similar
for most categories across treatment arms (Table 1). On average,
28% of the aneurysms across both arms were ruptured (HES:
76, 25.6%, BPC: 93, 30.9%). Most patients enrolled in the trial
were female (HES: 238, 80.1%, BPC: 236, 77.9%), and the mean
(SD) age of patients in the HES and BPC arms was 56.65 (11.5)
and 56.9 (10.3), respectively. Furthermore, aneurysm location,
the size and shape of the aneurysms, dome-to-neck ratio, and
the use of assist devices were similar for both arms. Of note, the
number of internal carotid artery aneurysms in the HES arm
(76 aneurysms, 26.6%) was lower than in the BPC arm (99
aneurysms, 34.0%).
Primary Endpoint
The odds of recurrence (defined as any progression on the RR
scale) for BPC relative to HES was 2.32 (95% CI [1.35, 3.97])
using an intent-to-treat imputation analysis (in which 46 patients’
outcomes were imputed in the HES arm and 37 in the BPC arm).
As per-protocol analysis, aneurysm recurrence was observed in 11
(4.4%) patients in the HES arm and 41 (15.4%) patients in the
BPC arm (OR 3.97 95% CI [1.99, 7.92]). After adjusting for
aneurysm size, rupture status, aneurysm neck size, and procedural
angiographic occlusion, results still favored greater occlusion in
the HES arm (OR 2.58 95% CI [1.05, 6.34]). A conservative
intent-to-treat analysis assuming that all subjects with no imaging
follow-up had aneurysm recurrence showed a similar trend, but
failed to reach statistical significance (OR 1.46 95% CI [0.99,
2.15]). Results are presented in Tables 2 and 3.
Secondary Endpoints
A total of 33 (13%) of HES and 71 (27%) of BPC showed
recurrence based on the Meyers scale (defined as any progression
on the Meyer scale), P < .001. Similarly, major recurrence
(defined by an increase on the RR scale from 1 to 3, 2 to 3, or a 3
that had progression on the Meyer scale) was seen in 32 (12.8%)
of HES, and 55 (20.7%) in BPC, and minor recurrence (defined
by an increase on the RR scale from 1 to 2) was seen in 2 (1%)
of HES and 14 (5%) of BPC (P = .016 and .004, respectively).
Packing density of the aneurysms was assessed in 238 HES and
237 BPC participants. HES had an average packing density of
32.5% (SD 14.8%), whereas BPC had an average packing density
of 24.7% (SD 10.2%), P < .001. On average, there were 4.9
(SD = 3.1) coils used in HES procedures and 5.6 (SD = 4.0) coils
in BPC. The average coil lengths were 8.5 cm (SD = 4.5) and
9.0 cm (SD = 4.9), respectively. Initial complete occlusion was
seen in 50 (17.8%) subjects in the HES group, as compared to 82
(28.3%) in the BPC group (P = .003). However, it appeared that
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FIGURE 3. HEAT participant flow CONSORT diagram.22

the percentage of aneurysms with complete occlusion increased in
the HES arm throughout imaging follow-up at a higher rate than
in the BPC arm (P < .001); estimated complete occlusion rates
were 64.9% and 49.0% at 3- to 12-mo and 68.6% and 51.5%
at 18- to 24-mo for HES and BPC, respectively. A total of 16
patients expired over the course of the study: 7 (2.4%) in HES
and 9 (3.0%) in BPC (OR 0.80 95% CI [0.29, 2.17]). There
was no difference in mRS at final follow-up between subjects in
the HES and BPC arms (P = .578). Aneurysm retreatment was
noted in 13 (5.2%) of HES and 22 (8.3%) of BPC (OR 0.61
95% CI [0.30, 1.23]). Analysis of adverse events related to the
procedure and/or the device as well as hemorrhage from the target

NEUROSURGERY

aneurysm during follow-up are presented in the Harms section
below.
Harms
A total of 597 adverse events were recorded by the investigators,
equally distributed between arms: 286 (47.9%) in the HES arm
and 311 (52.1%) in the BPC arm (P = .306). Among these,
177 were classified as SAEs: 92 (52.0%) in the HES arm and
85 (48.0%) in the BPC arm (P = .196) (Table, Supplemental
Digital Content 2). The serious and nonserious adverse events
are listed in Tables, Supplemental Digital Content 2 and 3,
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TABLE 1. Baseline Characteristics of Subjects in the HEAT Study
Hydrogel coil
297

Bare platinum
303

238 (80.1)
59 (19.9)

236 (77.9)
67 (22.1)

56.5 ± 11.5

56.9 ± 10.3

216 (74.0)
76 (26.0)

208 (69.1)
93 (30.9)

14 (18.4)
39 (51.3)
22 (28.9)
1 (1.3)

21 (22.3)
47 (50.0)
26 (27.7)
0 (0.0)

3.20 ± 1.40

3.00 ± 1.10

33 (11.6)
251 (88.4)
7.30 ± 2.70

21 (7.4)
263 (92.6)
7.50 ± 2.70

54 (18.9)
59 (20.6)
173 (60.5)

60 (20.5)
69 (23.6)
163 (55.8)

156 (54.5)
86 (30.1)
44 (15.4)

141 (48.3)
107 (36.6)
44 (15.1)

10 (3.5)
70 (24.5)
35 (12.2)
76 (26.6)
39 (13.6)
51 (17.8)
5 (1.7)

7 (2.4)
64 (22.0)
34 (11.7)
99 (34.0)
29 (10.0)
53 (18.2)
5 (1.7)

224 (76.7)
68 (23.3)

227 (75.2)
75 (24.8)

73 (24.6)
224 (75.4)

87 (28.7)
216 (71.3)

116 (39.7)
71 (24.3)
105 (36.0)

114 (37.7)
88 (29.1)
100 (33.1)

Sex
Female
Male
Age
(Mean ± SD)
Ruptured status
Unruptured
Ruptured
If ruptured, Hunt and Hess
1
2
3
4
Neck size
(mm)
Dome-to-neck ratio
≤1.5
>1.5
Maximum diameter (mm)
Shape
Daughter sac
Irregular
Regular
Type
Bifurcation
Sidewall
Terminal
Location
Anterior cerebral artery
Anterior communicating artery
Basilar artery
Internal carotid artery
Middle cerebral artery
Posterior communicating artery
Vertebral artery
Family history of aneurysm
No
Yes
Co-morbid conditions
No
Yes
Smoking status
Current smoker
Never smoked
Past smoker

respectively. The SAEs included 3 hydrocephalus events designated as device related by the site investigators in the HES arm
with none in the BPC arm. All 3 cases were in the posterior circulation and occurred after 1 yr of follow-up. There were 2 events
designated as unanticipated adverse events, the first being one of
the aforementioned hydrocephalus cases attributed to the device
and a second case of coil detachment in the HES arm.
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TABLE 2. Primary Outcome Analyses
P value

Model

OR and 95% CI

Intent to treat (multiple
imputation)
Univariate per protocol
Adjusted per protocol
Intent to treat (missing
assumed to recur)

2.32 (1.356, 3.97)

.002

3.97 (1.99, 7.92)
2.58 (1.05, 6.34)
1.46 (0.99, 2.15)

<.001
.039
.055

There were 176 adverse events related to the procedure and/or
the device occurring in 139 patients: 64 (21.6%) in HES and 75
(24.8%) in BPC (P = .352). In each arm, the number of adverse
events per person ranged from 0 to 3, with no significant trend in
number of events per arm (OR 0.84 95% CI [0.57, 1.22]). There
were 16 incidents of intracranial hemorrhage in 15 patients; of
these, 9 were either related to device or procedure: 5 in HES and
4 in BPC (P = .714). Seven were procedural events and 2 were
post-procedural. Due to lack of further information on the source
of bleeding from the post-procedural hemorrhages, we assumed
that both events were hemorrhages from target aneurysms during
follow-up (2 in the HES arm and 0 in the BPC arm).
The data that support the findings of this study are available
from the corresponding author upon reasonable request.

DISCUSSION
Background
Over the past 3 decades, BPC has been considered the standard
of care for endovascular aneurysm occlusion.23,24 More recently,
there have been significant advancements in coil design and
deployment techniques that have broadened the spectrum of
aneurysms amenable to coil embolization and, to an extent,
have improved the outcomes of aneurysm coiling.24-26 Despite
this progress, recurrence remains high and continues to be a
limitation of endovascular treatment.27,28 Multiple enhanced coil
designs including bioactive and surface modified coils have not
succeeded in showing a convincing reduction in aneurysm recurrence.6-9,29 In the MAPS trial, recurrence (with a follow-up of
455 d) was 13.3% in aneurysms treated with the bioactive Matrix
coils (Stryker, Kalamazoo, Michigan) and 14.6% for those treated
with BPC (P = .76).6 In the Cerecyte coil trial (Micrus Endovascular, San Jose, California), the occlusion status of aneurysms
(complete/stable/improved) at a median follow-up time of 6 mo
was similar between aneurysms coiled with the bioactive Cerecyte
coils and BPC (P = .17).7
On the other hand, the first-generation HES demonstrated
evidence of better outcomes as compared to BPC in several
clinical studies. The HEAL registry, which assessed recurrence
in aneurysms treated with various percentages of first-generation
HES length, showed that the use of a higher percentage of HES
was associated with lower recurrence rates at 3 to 6 mo.30 Notably,
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TABLE 3. Primary and Secondary Outcomes

Recurrence: any progression on the RR scale
Occlusion stability: any increase on the Meyers scale
Minor recurrence: progression on the RR scale from 1 to 2
Major recurrence: progression on the RR scale to 3, or a 3 with an
increase in the Meyers scale
Packing density
Initial occlusion
Occlusion stability
3-12 mo
18-24 mo
Patients with adverse eventsa
Adverse events per persona
None
One
Two
Three
Mortality
Clinical outcome
No symptoms
No significant disability
Slight disability
Moderate disability
Moderately severe disability
Severe disability
Expired
Retreatment
Hemorrhagea
a

HydroCoil Embolic System

Bare platinum coils

P value

4.4%
13%
2 (1.0%)
32 (12.8%)

15.4%
27%
14 (5.0%)
55 (20.7%)

.002
<.001
.004
.016

32.5% ± 14.8%
50 (17.8%)

24.7% ± 10.2%
82 (28.3%)

<.001
.003
<.001

64.9%
68.6%
64 (21.6%)

49.0%
51.5%
75 (24.8%)

233 (78.5%)
44 (14.8%)
19 (6.4%)
1 (0.3%)
7 (2.4%)

228 (75.3%)
63 (20.8%)
8 (2.6%)
4 (1.3%)
9 (3.0%)

181 (63.1%)
60 (20.9%)
24 (8.4%)
13 (4.5%)
2 (0.7%)
0 (0%)
7 (2.4%)
13 (5.2%)
5 (1.7%)

178 (61.0%)
63 (21.6%)
28 (9.6%)
10 (3.4%)
0 (0%)
4 (1.4%)
9 (3.1%)
22 (8.3%)
4 (1.3%)

.352
.294

.641
.578

.162
.714

Event related to device and/or procedure.

patients with ≥75% of HES had no recurrence (0/18 subjects).
Subsequently, HELPS, the first randomized controlled trial of
HES, showed lower major recurrence (over an 18-mo followup) associated with the use of first-generation HES as compared
to BPC (24% vs 33%, OR: 0.73, P = .049).3 The PRET trial
also evaluated recurrence over an 18-mo follow-up period in
aneurysms treated with HES in comparison to BPC.16,31 PRET-1
evaluated aneurysms ≥10 mm in size, and PRET-2 was focused
on aneurysms that had recurred after prior coiling. For both
groups, major recurrence was similar between the HES and BPC
arms.
Although the first-generation HES demonstrated results
trending towards better durability than BPC, handling characteristics prevented widespread adoption. In an attempt to overcome
the technical difficulties associated with the first-generation HES,
a second-generation HES was developed. The latter coil is
constructed with a filament of expandable hydrogel within the
platinum coil unlike the first-generation coil that has an exterior
hydrogel coating. The second-generation HES coils are as soft as
platinum coils and thus have handling properties similar to BPC.
Furthermore, the second-generation HES coils do not require
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any additional preparation prior to introduction into the microcatheter and they allow for longer repositioning time due to slower
and reduced expansion of the gel (up to 30 min).
The GREAT trial was the first randomized, controlled trial
to compare the second-generation HES to BPC.32 This trial
used a composite primary endpoint that included major recurrence, retreatment, morbidity, and mortality. Over a follow-up
period of 18 mo, the primary endpoint of GREAT trial was
lower in the HES arm (19.9% vs 28.7%); when adjusted for
rupture status, the results were still in favor of the HES arm
(P = .036). Notably, major recurrence rate was lower in the
HES arm (12% vs 18%). The HELPS, PRET, and GREAT
studies had a composite endpoint that included angiographic
and clinical outcomes.3,31,32 Clinical outcomes after aneurysm
treatment depend upon multiple factors besides aneurysm
occlusion including patient age, comorbidities, aneurysm rupture
status, etc. Aneurysm recurrence is a clinically relevant parameter
to define the success of aneurysm treatment. The clinical
importance of durable aneurysm occlusion is the prevention of
(re)hemorrhage. However, (re)hemorrhage itself occurs at such
a low incidence that it does not represent a pragmatic primary
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endpoint for a randomized controlled trial—ie, a randomized
controlled trial predicated upon (re)hemorrhage rates would
require a much larger sample size and much longer follow-up.
As such, aneurysm recurrence based upon radiological followup represents a well-accepted, reliable, and pragmatic surrogate
endpoint. Given these considerations, the HEAT trial was
powered with a primary focus on recurrence.
Key Findings
The primary endpoint of the HEAT trial (any progression on
the RR scale within 24 mo) was in favor of the HES arm (intentto-treat, OR 2.32 95% CI [1.35, 3.97]). The sensitivity analysis
adjusting for aneurysm size, rupture status, aneurysm neck size,
and procedural angiographic occlusion was also in favor of the
HES arm (OR 2.58 CI 95% [1.05, 6.34]). These analyses demonstrate that HES reduces recurrence rates in aneurysms between 3
and 14 mm in size, regardless of their rupture status, aneurysm
neck size, and procedural angiographic occlusion.
Generalizability
While the HEAT trial primary endpoint was based upon
progression on the RR scale, we additionally assessed major and
minor recurrences as well as aneurysm occlusion stability assessed
by any decrease in volumetric occlusion as defined in the Meyers
scale. Major recurrence was defined as any progression on the RR
scale to 3 or any 3 that had a decrease in volumetric occlusion
(using the Meyers scale). Major recurrence was defined by HELPS
and PRET as large recanalization requiring placement of further
coils and by GREAT as any increase on the RR scale or any
volumetric change in aneurysms with residual dome.3,31,32 In
HEAT, major recurrence and aneurysm occlusion stability were
both in favor of the HES arm. Although recurrence is directly
linked to retreatment, retreatment rates with HES were not statistically different from BPC (P = .162) in HEAT. It should be
noted that the need for retreatment has been reported in the literature even beyond 15 yr of follow-up.33
Interpretation
With respect to initial complete occlusion, the HES arm was
associated with a significantly lower rate of complete initial procedural occlusion than the BPC arm (17.8% vs 28.3%, P = .003).
However, complete occlusion was higher for the HES arm at 3to 12-mo and 18- to 24-mo imaging (P < .001). This could
be explained by a gradual hydrogel expansion that occurs 20 to
30 min post-deployment. Conversely, the GREAT trial results
showed higher initial complete occlusion in the HES arm.32 One
should note that they used up to 50% BPC while the HEAT trial
only allowed up to 10% use of BPC. The average percentage of
HES used in the HES arm of HEAT was 95.3%. The analysis
indicated higher packing density in the HES arm (P < .001).
Packing density was also in favor of the HES arm of PRET
and GREAT; however, PRET showed no difference in recurrence
between HES and BPC.31,32
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Overall adverse events and clinical outcomes in HEAT were
similar in both arms. The most common SAEs were stroke and
vasospasm. While no a priori plans were made to compare specific
SAEs between treatment arms, it is notable that the OR and 95%
CI for these 2 events comparing HES and BPC were 1.41 (0.64,
3.13) and 0.65 (0.30, 1.41), respectively. With regard to the 3
cases of hydrocephalus in the HES arm, all 3 were in unruptured
aneurysms with maximal diameters of 6.8, 10.5, and 13.5 mm
and occurred in a delayed fashion at 70, 57, and 54 wk following
endovascular coiling, respectively. All 3 aneurysms were in the
posterior circulation, involving the basilar tip (n = 2) and vertebrobasilar junction (n = 1). All 3 patients required placement
of a ventriculoperitoneal shunt and ultimately all had excellent
clinical outcomes. The observation that all 3 hydrocephalus cases
occurred in patients treated with HES might suggest relatedness
to the HES device. However, the delayed occurrence (greater
than 1 yr) argues against this. In the GREAT trial, 3 cases of
hydrocephalus were reported—2 in in the HES arm and 1 in
the platinum arm—and the events were adjudicated as unrelated
to the coil type. One of the plausible mechanisms specific to
basilar tip aneurysms is the possible obstruction of the cerebral
aqueduct by the mass of the aneurysm, which could theoretically
be exasperated by a coil mass.23,24
Limitations
Several limitations were encountered in the HEAT trial. The
trial randomization was not stratified based on baseline characteristics relevant to aneurysm prognosis. This resulted in minor
imbalances in some aneurysm characteristics, including aneurysm
location. Packing density was based upon the assumption of
an ellipsoidal shape for all aneurysms—this is not completely
accurate, especially in cases of irregular aneurysms. This
assumption can underestimate the volume of some aneurysms
and thereby overestimate the packing densities. In addition,
the packing density calculation in the HES arm assumed full
volumetric expansion of the gel, which might have not occurred in
vivo. Of note, the average packing density calculation in each arm
was not based on the packing density of all treated aneurysms, as
the information provided on some of the coils was incomplete and
did not allow for the determination of coil diameter (an essential
metric for packing density calculation).
While all adverse events were recorded, data on the source of
hemorrhagic events were not requested with sufficient specificity
in regard to whether the hemorrhages were related to the target
aneurysm or not. However, postoperative hemorrhages related
to device and/or procedure were captured and reported by the
sites. A retrospective review of clinical documentation for both
patients with such postoperative hemorrhages was performed.
Only one hemorrhage—in the HES arm—was found to be
a post-procedural subarachnoid hemorrhage from the treated
aneurysm. The event happened 6 h following the endovascular
coiling procedure. The other patient experienced a same day postprocedural subarachnoid hemorrhage with an unclear source of
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bleeding. This patient had a total of 5 aneurysms, and the treating
physician felt that the targeted aneurysm was not convincingly
the source of bleeding. With respect to the procedure, the treating
physicians were not blinded to the treatment arm, but the imaging
Core Lab physicians were, which strengthens the validity of the
imaging results. The attrition rate was 13.8%, 15.5% for HES
and 12.2% for BPC. Finally, the trial was not powered to detect
the effect of HES in reducing retreatment rates and long-term
clinical outcomes beyond 2 yr.

CONCLUSION
The results of the HEAT trial demonstrate statistically significant reduced recurrence rates in 3- to 14-mm-sized ruptured
and unruptured intracranial aneurysms treated with secondgeneration HES when compared to aneurysms treated with
BPC. There were no significant differences in procedural safety
and clinical outcomes detected between the 2 treatment arms
throughout the period of the study. Despite expected limitations,
the primary findings of the HEAT trial provide evidence in favor
of using second-generation HES over BPCs for the endovascular
coiling of small-to-medium-sized intracranial aneurysms.
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